Skip to main content

Day: June 21, 2025

BioAge Labs to Present Preclinical Data on APJ Agonism for Diabetic Obesity and Heart Failure at the American Diabetes Association (ADA) 85th Scientific Sessions

Treatment with apelin receptor agonist enhanced glycemic control and demonstrated cardioprotective effects, with additive benefits observed in combination with incretin therapy Data support development of next-generation APJ agonists for obesity and key comorbidities EMERYVILLE, Calif., June 21, 2025 (GLOBE NEWSWIRE) — BioAge Labs, Inc. (Nasdaq: BIOA) (“BioAge”, “the Company”), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced that it will present new preclinical data supporting apelin receptor (APJ) agonism for the treatment of diabetic obesity and heart failure with preserved ejection fraction (HFpEF). The data will be presented at the American Diabetes Association’s 85th Scientific Sessions, held June 20–23,...

Continue reading

Canadian North Resources Announces Results of 2025 Annual and Special Meeting of Shareholders

TORONTO, June 21, 2025 (GLOBE NEWSWIRE) — Canadian North Resources Inc. (“CNRI” or “the Company,” TSXV: CNRI; OTCQX: CNRSF; FSE: EO0 (E-O-zero) is pleased to announce the voting results of its Annual and Special Meeting of Shareholders held on June 19, 2025, in Mississauga, Ontario. A total of 73,621,572 common shares were voted at the Meeting, representing approximately 64.4% of the Company’s issued and outstanding common shares (114,325,317). Election of Directors Shareholders approved the re-election of all five nominees to the Board of Directors. The directors elected to hold office until the next annual meeting of shareholders or until their successors are duly elected or appointed are:Nominee % For % WithheldLee Q. Shim 99.99%   0.00%  Kaihui Yang 99.99%   0.00%  Aier Wang 99.99%   0.00%  Henderson Tse 99.99%   0.00%  Michael...

Continue reading

Perspective Therapeutics Presents at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2025 Annual Meeting

SEATTLE, June 21, 2025 (GLOBE NEWSWIRE) — Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, announced two presentations on its assets being delivered at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2025 Annual Meeting taking place June 21-24, 2025 in New Orleans, Louisiana.Lead author Abstract Title Presentation DetailsStephen Graves [212Pb]Pb-VMT-α-NET dosimetry in patients with advanced SSTR2-positive tumors in the VMT-α-NET-T101 trial Abstract Number: 251949Session Type: Poster & OralPoster Session Date: June 21, 2025Oral session: MTA07 Oncology: Clinical Diagnosis & Therapy Meet the Author Session, part 2 Oral Session Date: June 23, 2025Oral Session Time: 12:30 PM...

Continue reading

Perspective Therapeutics Commences Recruitment for [212Pb]VMT-α-NET in the Third Dose Escalation Cohort of its Ongoing Phase 1/2a Clinical Trial

[212Pb]VMT-α-NET Phase 1/2a study is advancing into Cohort 3 with a fixed administered dose that is up to 20% higher (6 mCi) than the dose administered to patients in Cohort 2 Dosimetry sub-study analysis presented at the Society of Nuclear Medicine & Molecular Imaging (SNMMI) 2025 Annual Meeting to advance utility of dosimetry in clinical development when considered with clinical data On track to submit further clinical updates to scientific congresses in 2H 2025, including longer safety follow-up on all patients who have received at least one treatment of [212Pb]VMT-α-NET and anti-tumor activities in patients dosed to date who have had the opportunity to receive at least one scan after their full treatmentSEATTLE, June 21, 2025 (GLOBE NEWSWIRE) — Perspective Therapeutics, Inc. (“Perspective” or the “Company”)...

Continue reading

Jane Silverstone Segal Increases Number of Shares of DAVIDsTEA Inc. Under Her Control

MONTREAL, June 20, 2025 (GLOBE NEWSWIRE) — Jane Silverstone Segal, Chair of the Board of Directors of DAVIDsTEA Inc. (“DAVIDsTEA”) (TSXV: DTEA), announces that on June 20, 2025, she received shares of Rainy Day Investments Ltd. (“RDI”) by way of bequest from her late husband Mr. Herschel Segal, as a result of which Jane Silverstone Segal has voting control of RDI. RDI owns 12,012,538 common shares of DAVIDsTEA, representing 44.51% of DAVIDsTEA’s issued and outstanding common shares, which shares are now controlled by Jane Silverstone Segal. Immediately prior to the transfer of shares described above, Jane Silverstone Segal held 127,087 common shares of DAVIDsTEA, representing 0.47% of its 26,985,738 issued and outstanding common shares. Immediately after the transfer of shares described above, Mrs. Segal holds or exercises control,...

Continue reading

Enzon and Viskase Enter into Merger Agreement

Enzon and Viskase stockholders will respectively own approximately 15.9% and 84.1% of the combined company CRANFORD, N.J. and LOMBARD, Ill., June 20, 2025 (GLOBE NEWSWIRE) — Enzon Pharmaceuticals, Inc. (OTCQX: ENZN) (“Enzon” or the “Company”) and Viskase Companies, Inc. (OTC Pink Limited: VKSC) (“Viskase”) announced that they have entered into a definitive merger agreement (the “Merger Agreement”), pursuant to which Viskase will merge with and into a wholly owned subsidiary of Enzon in an all-stock transaction (the “Merger”). Following the Merger, the combined company is expected to operate under the name “Viskase Holdings, Inc.” and will trade on the “OTCQX” tier of the OTC market of the OTC Markets Group, Inc. The Chief Executive Officer of Viskase Holdings will be Timothy P. Feast, who is currently the Chief Executive Officer...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.